Pixium Vision announces the conversion of the safeguard proceedings into receivership
13 November 2023 - 8:00PM
Pixium Vision announces the conversion of
the safeguard proceedings into receivership
Paris, France, November 13,
2023 – 8:00 pm
(CET ) – Pixium Vision SA (Euronext Growth Paris -
FR001400JX97; Mnemo: ALPIX), a bioelectronics company developing
innovative vision systems to enable patients who have lost their
sight to live more independent lives, today announces the
conversion of the safeguard proceedings (procédure de sauvegarde)
which has been in place since October 9, 2023 into receivership
(redressement judiciaire).
As announced on October 18, 2023, in the absence
of a solution to strengthen its financial situation and secure its
cash runway during the safeguard proceedings, Pixium together with
the court-appointed administrators, filed a request with the
Commercial Court of Paris for the conversion of the safeguard
proceedings into receivership. This request was examined and
approved by the Commercial Court of Paris at the hearing of
November 13, 2023.
In this context, Pixium reiterates that a
bidding process for the purpose of finding buyers to acquire the
Company’s business has been published by the court-appointed
administrators on October 20, 2023 and that the deadline for the
submission of offers has been set to November 20, 2023 at 12:00
p.m. (noon).
Interested candidates are invited to contact the
court-appointed administrators, SCP Abitbol & Rousselet,
represented by Joanna Rousselet, and Selarl FHB, represented Hélène
Bourbouloux.
Access to an electronic data room will be
granted once the candidate has signed a confidentiality agreement
and submitted a brief presentation of interest.
The Company draws investors’ attention to the
possibility that, in the event of a court-order plan to sell off
all or part of the Company’s assets, the price offered may not
allow shareholders to be reimbursed in full or in part.
The market will be regularly informed on the
progress of the procedure and, more generally, on the financial
situation of Pixium.
About Pixium Vision
Pixium Vision is creating a
world of bionic vision for those who have lost their sight,
enabling them to regain visual perception and greater autonomy.
Pixium Vision’s bionic vision systems are associated with a
surgical intervention and a rehabilitation period. Prima System
sub-retinal miniature photovoltaic wireless implant is in clinical
testing for patients who have lost their sight due to outer retinal
degeneration, initially for atrophic dry age-related macular
degeneration (dry AMD). Pixium Vision collaborates closely with
academic and research partners, including some of the most
prestigious vision research institutions in the world, such as
Stanford University in California, Institut de la Vision in Paris,
Moorfields Eye Hospital in London, Institute of Ocular Microsurgery
(IMO) in Barcelona, University hospital in Bonn, and UPMC in
Pittsburgh, PA. The Company is EN ISO 13485 certified and qualifies
as “Entreprise Innovante” by Bpifrance.
For more information:
http://www.pixium-vision.com/fr
Follow us on @PixiumVision;
www.facebook.com/pixiumvision
www.linkedin.com/company/pixium-vision
Contacts
Investor
RelationsPixium VisionOffer NonhoffChief
Financial Officerinvestors@pixium-vision.com |
Media
Relations Rose Piquante ConsultingSophie
BaumontSophie.baumont@rosepiquante-consulting.com+33 6 27 74 74
49 |
- Pixium - PR conversion receivership - draft 12.11.23
Pixium Vision (EU:ALPIX)
Historical Stock Chart
Von Apr 2024 bis Mai 2024
Pixium Vision (EU:ALPIX)
Historical Stock Chart
Von Mai 2023 bis Mai 2024